Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513200 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia
A Phase 1 study, sponsored by Stealth BioTherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01513200 is a Phase 1 study that has completed, run by Stealth BioTherapeutics. The registered enrollment target is 12 participants.
The verdict
NCT01513200, a Phase 1 study, has completed, sponsored by Stealth BioTherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This will be a phase 1 randomized, double-blind crossover trial enrolling approximately 12 healthy volunteers to assess whether intravenous (IV) UFH and IV Bendavia administered together have any significant impact on the pharmacodynamic effects of UFH and the pharmacokinetics of Bendavia.
Interventions
- DRUG Unfractionated heparin (UFH)
- DRUG Bendavia
- DRUG Saline (0.9%, sterile, for infusion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01513200
The ClinicalTrials.gov registry entry for NCT01513200 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Unfractionated heparin (UFH) is the first listed.
NCT01513200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01513200 about?
NCT01513200 is a clinical study titled "Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia". This will be a phase 1 randomized, double-blind crossover trial enrolling approximately 12 healthy volunteers to assess whether intravenous (IV) UFH and IV Bendavia administered together have any significant impact on the pharmacodynamic effects of UFH and the pharmacokinetics of Bendavia.
What is the current status of trial NCT01513200?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-01. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01513200?
The interventions under investigation include: Unfractionated heparin (UFH) (DRUG), Bendavia (DRUG), Saline (0.9%, sterile, for infusion) (DRUG).
Who is sponsoring clinical trial NCT01513200?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.